Apeiron Capital Investment Corp. (APN) Financial Statements (2025 and earlier)
Company Profile
| Business Address |
175 FEDERAL STREET BOSTON, MA 02110 |
| State of Incorp. | DE |
| Fiscal Year End | December 31 |
| Industry (SIC) | 2836 - Biological Products, Except Diagnostic Substances (benchmarking) |
| More info | Complete Financial Analysis Financial Benchmarking |
Balance Sheet (Statement of Financial Position) (USD)
| 3/31/2023 MRQ | 12/31/2022 | 12/31/2021 | |||
|---|---|---|---|---|---|
| ASSETS | |||||
| Current Assets | |||||
| Cash, cash equivalents, and short-term investments | 1,094,384 | 751,572 | |||
| Cash and cash equivalents | 1,094,384 | 751,572 | |||
| Prepaid expense | 177,083 | 234,215 | |||
| Total current assets: | 1,271,467 | 985,787 | |||
| Noncurrent Assets | |||||
| Prepaid expense | 177,083 | ||||
| Asset, held-in-trust | 16,182,549 | 175,952,082 | |||
| Total noncurrent assets: | 16,182,549 | 176,129,165 | |||
| TOTAL ASSETS: | 17,454,016 | 177,114,952 | |||
| LIABILITIES AND EQUITY | |||||
| Liabilities | |||||
| Current Liabilities | |||||
| Accounts payable and accrued liabilities | 830,785 | 191,193 | |||
| Accrued liabilities | 830,785 | 191,193 | |||
| Other undisclosed current liabilities | 1,305,103 | ||||
| Total current liabilities: | 2,135,888 | 191,193 | |||
| Noncurrent Liabilities | |||||
| Other undisclosed noncurrent liabilities | 11,598,750 | 17,655,750 | |||
| Total noncurrent liabilities: | 11,598,750 | 17,655,750 | |||
| Total liabilities: | 13,734,638 | 17,846,943 | |||
| Temporary equity, carrying amount | 15,381,820 | ||||
| Equity | |||||
| Equity, attributable to parent, including: | (11,662,442) | (16,681,991) | |||
| Accumulated deficit | (11,662,873) | (16,682,422) | |||
| Other undisclosed equity, attributable to parent | 431 | 431 | |||
| Other undisclosed equity | 175,950,000 | ||||
| Total equity: | (11,662,442) | 159,268,009 | |||
| TOTAL LIABILITIES AND EQUITY: | 17,454,016 | 177,114,952 | |||
Income Statement (P&L) (USD)
| 3/31/2023 TTM | 12/31/2022 | 12/31/2021 | ||
|---|---|---|---|---|
| Operating expenses | (1,203,615) | (234,315) | ||
| Operating loss: | (1,203,615) | (234,315) | ||
| Nonoperating income | 8,375,006 | 720,788 | ||
| Investment income, nonoperating | 2,318,006 | 2,082 | ||
| Income from continuing operations before income taxes: | 7,171,391 | 486,473 | ||
| Income tax expense (benefit) | (588,493) | 48,769 | ||
| Income from continuing operations: | 6,582,898 | 535,242 | ||
| Income before gain (loss) on sale of properties: | ✕ | 535,242 | ||
| Other undisclosed net loss | (48,769) | |||
| Net income attributable to parent: | 6,582,898 | 486,473 | ||
| Preferred stock dividends and other adjustments | (1,563,349) | (20,555,464) | ||
| Other undisclosed net loss available to common stockholders, basic | ||||
| Net income (loss) available to common stockholders, diluted: | 5,019,549 | (20,068,991) | ||
Comprehensive Income (USD)
| 3/31/2023 TTM | 12/31/2022 | 12/31/2021 | ||
|---|---|---|---|---|
| Net income: | 6,582,898 | 486,473 | ||
| Comprehensive income, net of tax, attributable to parent: | 6,582,898 | 486,473 | ||
Statements Sources
The financial statements are based on the Company's filings with the U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.